NEFL and Alzheimer disease: A possible explanation is that p-tau181 is a more specific biomarker for AD pathology compared with NfL (Chatterjee et al., 2022; Sarto et al., 2022), the impact of renal function on p-tau181 levels may be weaker in A+.